Braf V600e
Braf V600e - Related Videos
10:16
Employing Digital Droplet PCR to Detect BRAF V600E Mutations in Formalin-fixed Paraffin-embedded Reference Standard Cell Lines
0 Views •
Cited by 2 •
2015
The goal of this video is to demonstrate how to perform automated DNA extraction from formalin-fixed paraffin-embedded (FFPE) reference standard cell lines and digital droplet PCR (ddPCR) analysis to detect rare mutations in a clinical setting. Detecting mutations in FFPE samples demonstrates the clinical utility of ddPCR in FFPE samples.
08:18
Analysis of Lymph Node Volume by Ultra-High-Frequency Ultrasound Imaging in the Braf/Pten Genetically Engineered Mouse Model of Melanoma
0 Views •
Cited by 2 •
2021
Melanoma is a very aggressive disease that quickly spreads to other organs. This protocol describes the application of ultra-high-frequency ultrasound imaging, coupled with 3D rendering, to monitor the volume of the inguinal lymph nodes in the Braf/Pten mouse model of metastatic melanoma.
13:24
Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies
0 Views •
Cited by 2 •
2016
An integrated system for targeted next-generation sequencing of oncology specimens is described. This cross-platform system is optimized for low-quality and low-quantity tumor biopsies, accommodates low DNA inputs, includes well-characterized multi-variant controls, and features a novel variant caller that is informed by quantitative pre-analytical quality control measures.
05:17
Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing
0 Views •
2025
This protocol describes an automated, ISO15189-accredited next-generation sequencing workflow for detecting targetable genomic alterations in non-small cell lung cancer (NSCLC) formalin-fixed paraffin-embedded tissues.
10:23
Screening for Melanoma Modifiers using a Zebrafish Autochthonous Tumor Model
0 Views •
Cited by 32 •
2012
A rapid way to screen for melanoma modifiers using a zebrafish autochthonous tumor model is presented. It takes advantage of the miniCoopR vector which allows for expression of candidate melanoma genes in melanocytes. A method to obtain melanoma-free survival curves, an invasion assay, a protocol for antibody staining of scale melanocytes and a melanoma transplantation assay are described.
FAQs
Persistent activity keeps stimulating the MAPK pathway rather than allowing signaling to switch off normally. Because this pathway regulates cell proliferation and survival, continuous activation can support sustained tumor growth. This explains why identifying the mutation is clinically meaningful: it links a molecular alteration with a signaling process that can be addressed through pathway-directed treatment.
BRAF-targeted treatment focuses on the altered BRAF protein, whereas combined therapy targets BRAF and MEK within the same MAPK signaling pathway. The distinction is clinically important because the two approaches represent different ways to suppress pathway activity. BRAF V600E testing can therefore help identify patients for whom these targeted treatment strategies may be relevant.
The mutation provides molecular information in addition to the tumor’s anatomical site. Its presence can help classify a cancer according to a specific genetic feature and may contribute to prognostic assessment. This makes the result useful for interpreting tumor biology and supporting decisions that are not based solely on where the cancer originated.
Testing determines whether the tumor carries the BRAF V600E alteration, creating a biomarker result that clinicians can consider alongside other medical information. The finding may support tumor classification, inform prognosis, and identify patients who could benefit from BRAF-directed or combined BRAF and MEK inhibitor therapy. It therefore connects laboratory analysis with personalized treatment planning.
The mutation has clinical relevance across several cancers, including melanoma, colorectal cancer, and thyroid cancer. Its importance is not limited to one tumor type because the same molecular finding can assist classification and treatment planning in different diseases. In each setting, detection helps determine whether mutation-informed care may be appropriate.
A positive result can help match a patient’s tumor with therapies designed to act on the affected signaling system. Clinicians may use that information when considering a BRAF inhibitor or a combined BRAF and MEK inhibitor approach. The result does not replace broader clinical assessment, but it adds molecular evidence for selecting a more individualized treatment strategy.